| Syndrome . | Sex . | Mutation . | Age (yr) . | Treatment . | Figure . |
|---|---|---|---|---|---|
| MWS | M | T436A | 32 | Canakinumab | Fig. S1, E–H |
| FCAS | F | L353P | 86 | Rilonacept | Fig. S1, E–H |
| FCAS | F | L353P | 32 | Rilonacept | Fig. S1, E–H |
| NOMID | M | G326E | 13 | Anakinra | Fig. S2, G–I |
| MWS | F | R260W | 42 | Canakinumab | Fig. S2, G–I |
| FCAS | F | L353P | 74 | Canakinumab | Fig. S2, G–I |
| FCAS? | F | V198M | 46 | – | Fig. S2 J |
| FCAS | M | A439V | 48 | Canakinumab | Fig. 3 E |
| MWS | F | Q567K | 70 | – | Fig. S2 J |
| Syndrome . | Sex . | Mutation . | Age (yr) . | Treatment . | Figure . |
|---|---|---|---|---|---|
| MWS | M | T436A | 32 | Canakinumab | Fig. S1, E–H |
| FCAS | F | L353P | 86 | Rilonacept | Fig. S1, E–H |
| FCAS | F | L353P | 32 | Rilonacept | Fig. S1, E–H |
| NOMID | M | G326E | 13 | Anakinra | Fig. S2, G–I |
| MWS | F | R260W | 42 | Canakinumab | Fig. S2, G–I |
| FCAS | F | L353P | 74 | Canakinumab | Fig. S2, G–I |
| FCAS? | F | V198M | 46 | – | Fig. S2 J |
| FCAS | M | A439V | 48 | Canakinumab | Fig. 3 E |
| MWS | F | Q567K | 70 | – | Fig. S2 J |
F, female; M, male; NOMID, neonatal-onset multisystem inflammatory disease.